- 文献引用 : 1
|Application ||IHC-P, WB, E|
|Other Names||Bcl-2-interacting killer, Apoptosis inducer NBK, BIP1, BP4, BIK, NBK|
|Target/Specificity||This Bik BH3 Domain antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-74 amino acids from human Bik BH3 Domain.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Bik BH3 Domain Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Accelerates programmed cell death. Association to the apoptosis repressors Bcl-X(L), BHRF1, Bcl-2 or its adenovirus homolog E1B 19k protein suppresses this death-promoting activity. Does not interact with BAX.|
|Cellular Location||Endomembrane system; Single-pass membrane protein. Mitochondrion membrane; Single-pass membrane protein. Note=Around the nuclear envelope, and in cytoplasmic membranes|
Author : Sass G, Shembade ND, Haimerl F, Lamoureux N, Hashemolhosseini S, Tannapfel A, Tiegs G.
J Immunol. 2007 Nov 15;179(10):7042-9.
Provided below are standard protocols that you may find useful for product applications.
The Bik protein is known to interact with cellular and viral survival-promoting proteins, such as BCL2 and the Epstein-Barr virus in order to enhance programmed cell death. Because its activity is suppressed in the presence of survival-promoting proteins, this protein is suggested as a likely target for antiapoptotic proteins. This protein shares a critical BH3 domain with other death-promoting proteins, BAX and BAK.
Arena, V., et al., Genes Chromosomes Cancer 38(1):91-96 (2003).
Gillissen, B., et al., EMBO J. 22(14):3580-3590 (2003).
Germain, M., et al., J. Biol. Chem. 277(20):18053-18060 (2002).
Zou, Y., et al., Cancer Res. 62(1):8-12 (2002).
Castells, A., et al., Gastroenterology 117(4):831-837 (1999).